Thanks for the MST report it all makes perfect sense compounding revenue growth.
BTW it's looking very likely " finally " that MSB will get its remestemcel L FDA approved in the next 6 months for graft vs host disease which will lead to substantial revenue. Sometimes it pays to just show some patience and I am sure EYE will be hugely successful the writing is on the wall.
Thanks for the MST report it all makes perfect sense compounding...
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
-0.003(1.15%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.0¢ | 21.5¢ | $84.25K | 381.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 308826 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 1493 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.5¢ |
Change
-0.003 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 23.0¢ | 21.5¢ | 151833 | ||
| Last updated 15.15pm 13/06/2024 ? | |||||
| EYE (ASX) Chart |